$GGB

Japur Rafael Dorneles sold $24K of GGB

Japur Rafael Dorneles sold 5,000 shares of GERDAU S.A. (GGB) at $4.75 on 2026-05-22.

Original reporting
SEC EDGAR · Japur Rafael Dorneles
Published May 26, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GGB
Neutral
medium confidence
Mentioned
$GGB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GGBNeutralLow
01

Why it matters

Insider selling can modestly affect sentiment, but absent any accompanying corporate event, it typically has limited predictive power for price direction.

02

Market read

Traders may monitor for follow-on selling or confirm whether the transaction is part of a broader pattern, but no fundamental catalyst is provided.

03

What to watch

Check whether there are multiple recent insider transactions, whether other insiders/funds are trimming, and whether the sale coincides with upcoming earnings or material announcements.

Relevance 6/10Timing: Immediate awareness for positioning, but not a standalone catalyst.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Gerdau S.A. (GGB).

Company-level read

Ticker impact

$GGBNeutralMedium confidence
Context

SEC Form 4 shows insider Japur Rafael Dorneles sold 5,000 GGB shares in an open-market transaction on 2026-05-22.

Expected impact

Likely limited near-term impact; any move would be small and quickly mean-reverting unless followed by broader selling or company-specific news.

Evidence & confidence

Insider sales on Form 4 are common and often non-informational; the article provides no 10b5-1 plan and no accompanying operational/financial catalyst.

Market effects

Minimal—this is company-specific insider trading disclosure without sector-wide implications.

Minimal—no geographic or cross-border operational change described.

Minimal—no deal, guidance, or regulatory development affecting global demand or risk.

Counterpoint

The sale may be routine liquidity/portfolio management; without a 10b5-1 plan, it still lacks evidence of negative fundamentals.

Key entities

  • GERDAU S.A.

    Subject of the SEC Form 4 insider transaction; insider sold 5,000 shares at $4.75 on 2026-05-22.

  • Japur Rafael Dorneles

    Reporter of the open-market sale; holdings after transaction were 96,967 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GGBMed

Gerdau (GGB) Q3 2026 Earnings Call Transcript

Gerdau S.A. reported Q3 2026 earnings, highlighting BRL 1.7B free cash flow, BRL 0.34/share dividends, and a solid balance sheet. The company expects to return over BRL 1.85B to shareholders in 2026. North American operations showed strong demand, while Brazil faced seasonal slowdowns and import challenges. The company plans adjustments to improve Brazilian profitability and is awaiting government support on trade and energy policies.

$GGBMed

What Gerdau (GGB) Said on Its Q3 Earnings Call

Gerdau (GGB) is expanding capacity at its Texas facility, with full production expected by 2027. The company focuses on organic investments, not spin-offs or major acquisitions. Management discussed potential trade impacts on regional margins. In Brazil, Gerdau faces import pressure but plans productivity improvements. The company announced dividends and reduced capital expenditure plans to BRL 4 billion. Net debt to EBITDA is 0.58 times, with a positive outlook from S&P.

$GGBMedAI 8/10

Gerdau ADR earnings missed, revenue topped estimates

Gerdau ADR (GGB) reported Q3 EPS of $0.159, missing estimates of $0.165, while revenue of $3.75B exceeded expectations. The stock is down 4.23% over 3 months but up 37.28% year-over-year. Analysts revised EPS positively twice in the last 90 days. InvestingPro rates its financial health as good.